- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Apollomics Inc (APLM)
The Apollomics share price today is 28.0100, view NASDAQ APLM stock exchange data. Track the latest Apollomics share price with real-time updates on APLM stock performance including market cap, day range, 52-week range and dividend yield. Access APLM charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.5000
28.2900
52 wk Range
4.2100
42.1200
APLM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
27.500028.2900
52 wk Range
4.210042.1200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
APLM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Apollomics raises $10 million in private placement- Investing.com
Apollomics CFO Peter Lin buys $400,005 in shares- Investing.com
Form 4 Apollomics Inc For: 17 June- Investing.com
Apollomics COO Chen Yi-Kuei buys $300,000 in shares- Investing.com
- Apollomics CFO Peter Lin buys $400,005 in shares
- Investing.com
- Apollomics COO Chen Yi-Kuei buys $300,000 in shares
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Earnings
Latest Release
24-04-2026
EPS / Forecast
0.89 / --
Revenue / Forecast
342K / --
Compare APLM to Peers and Sector
Metrics to compare | APLM | Sector Sector - Average of metrics from a broad group of related Financial sector companies | Relationship RelationshipAPLMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −2.4x | −0.4x | |
PEG Ratio | −0.06 | −0.10 | 0.00 | |
Price/Book | −19.3x | 3.1x | 2.6x | |
Price / LTM Sales | 7.0x | 12.2x | 3.1x | |
Upside (Analyst Target) | - | 354.6% | 49.0% | |
Fair Value Upside | Unlock | 15.6% | 7.1% | Unlock |
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Apollomics (APLM) Share Price Today?
The Apollomics share price today is 28.0100.
What is the current Apollomics (APLM) share price and day range?
As of 03-09-2026, the Apollomics share price is 28.0100, with a previous close of 27.3462. The share price has ranged from 27.5000 to 28.2900 today, while the 52-week range spans from 4.2100 to 42.1200.
What Is the Apollomics Market Cap?
As of today, Apollomics market cap is 60.0500M.
What Is Apollomics's Earnings Per Share (TTM)?
The Apollomics EPS (TTM) is -7.5650.
From a Technical Analysis Perspective, Is APLM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Apollomics Trade On?
Apollomics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Apollomics?
The stock symbol for Apollomics is "APLM."
How Many Times Has Apollomics Stock Split?
Apollomics has split 1 times.
How Many Employees Does Apollomics Have?
Apollomics has 14 employees.
What Is the APLM Premarket Price?
APLM's last pre-market stock price is 27.2000. The pre-market share volume is 10.0000, and the stock has changed by -0.1462, or -0.5300%.
What Is the APLM After Hours Price?
APLM's last after hours stock price is 28.3200, the stock has changed by 0.3100, or 1.1100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.